At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 506 enrolled
Drug / intervention
Alogliptin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Determine the Efficacy and Safety of SYR-322 When Used in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Alogliptin, Placebo to alogliptin, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 506 participants across 21 sites in 3 countries.
Detailed Summary
The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesChina, Hong Kong, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedFeb 2011
Primary CompletionDec 2011
TodayJul 2026
First PostedFeb 3, 2011
Enrollment StartDec 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.4 years ago
Interventions
Alogliptindrug
Alogliptin tablets
Placebo to alogliptindrug
Alogliptin placebo-matching tablets.
Metformindrug
Stable metformin dose
Pioglitazonedrug
Stable pioglitazone dose